Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345452 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL1093384 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL29611701 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL29612126 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Hydrochloric Acid SCHEMBL1253712 | 0.98 | P4HTM (0.62) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Hydrochloric Acid SCHEMBL1253709 | 0.98 | P4HTM (0.62) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Acrylic Acid SCHEMBL6640512 | 0.93 | P4HTM (0.57) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Acrylic Acid SCHEMBL6640522 | 0.93 | P4HTM (0.57) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Trifluoroacetic Acid SCHEMBL1253588 | 0.91 | P4HTM (0.54) | P4HTMHCAR2CA12AKR1B10CA1 | |
| Trifluoroacetic Acid SCHEMBL1253589 | 0.91 | P4HTM (0.54) | P4HTMHCAR2CA12AKR1B10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | disclosed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-3016946-B1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114507215-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-108440515-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6127389-A | TREATMENT OF HYPERTENSION, RENAL DISEASES, HEART FAILURE, HYPERTENSION, MENIERE'S DISEASE, PERIPHERAL AND CEREBRAL CIRCULATORY DISORDERS, CLIMACTERIC DISTURBANCE, RETINOCHOROIDAL CIRCULATORY DISORDERS, MYOCARDIAL ISCHEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| US-6015818-A | TREATING KIDNEY, BRAIN, AND CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0879233-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-25 | — | — | EP | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997028153-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NAMPT, NQO1, NAPRT | P4HTM 1202/4885HCAR2 875/4885CA12 4626/4885 |
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | SARS1, ACE, PLPBP | P4HTM 1398/4885HCAR2 2300/4885CA12 4280/4885 |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | P4HTM 1018/4885HCAR2 3607/4885CA12 2349/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | P4HTM 2392/4885HCAR2 1750/4885CA12 4851/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | P4HTM 1018/4885HCAR2 3607/4885CA12 2349/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | P4HTM 858/4885HCAR2 1785/4885CA12 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.